You might not know it, but some of the helmets you seen worn by players on Sunday, Saturday and Friday nights during football ...

A limited-edition G-Class and an apparel capsule combine the legendary G-Wagen silhouette with a fashion-forward edge—because ...

The battle-scarred helmet the Kings received from two Los Angeles firefighters has proven to be a major good-luck charm, and ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

NEW YORK, March 27 (Reuters) - Merck & Co (MRK.N), opens new tab said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the ...

This is so cool! I just built up my brand new Marin Alcatraz dirt jump bike, and started riding my new Red Bull & TSG full face face, that's fully custom painted by Image Design Custom.

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck has recently achieved a significant milestone with the European Commission's approval of its pneumococcal vaccine CAPVAXIVE®, boosting its portfolio in the vaccines market. Despite this ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

It is MiLB’s first-ever season-long helmet decal partner. The company will also provide the apparel for the ballpark’s grounds crews, guest services employees and team executives. The brand’s exposure ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.